CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
CytomX Therapeutics (CTMX) has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after U.S. markets close. The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. Investors can access the webcast through CytomX's investor relations website, and an archived version will be available afterward.
CytomX Therapeutics (CTMX) ha annunciato che pubblicher脿 i suoi risultati finanziari del terzo trimestre 2024 gioved矛 7 novembre 2024, dopo la chiusura dei mercati statunitensi. L'azienda terr脿 una conference call e una trasmissione in webcast alle 17:00 ET / 14:00 PT per discutere i risultati. Gli investitori possono accedere al webcast tramite il sito web delle relazioni con gli investitori di CytomX, e una versione archiviata sar脿 disponibile successivamente.
CytomX Therapeutics (CTMX) ha anunciado que publicar谩 sus resultados financieros del tercer trimestre de 2024 el jueves 7 de noviembre de 2024, despu茅s del cierre de los mercados estadounidenses. La compa帽铆a llevar谩 a cabo una llamada de conferencia y una transmisi贸n web a las 5:00 p.m. ET / 2:00 p.m. PT para discutir los resultados. Los inversores pueden acceder a la transmisi贸n a trav茅s del sitio web de relaciones con inversores de CytomX, y una versi贸n archivada estar谩 disponible posteriormente.
CytomX Therapeutics (CTMX)電� 2024雲� 3攵勱赴 鞛 瓴瓣臣毳� 2024雲� 11鞗� 7鞚� 氇╈殧鞚�, 氙戈淡 鞁滌灔鞚� 毵堦皭霅� 頉勳棎 氚滍憸頃� 瓴冹澊霛缄碃 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 瓴瓣臣鞐� 雽�頃� 雲检潣頃橁赴 鞙勴暣 鞓ろ泟 5鞁�(ET) / 鞓ろ泟 2鞁�(PT)鞐� 旎嵓霟办姢 旖� 氚� 鞗轨簮鞀ろ姼毳� 歆勴枆頃╇媹雼�. 韴瀽鞛愲摛鞚� CytomX鞚� 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞗轨簮鞀ろ姼鞐� 鞝戧芳頃� 靾� 鞛堨溂氅�, 鞚错泟 鞎勳勾鞚措笇 氩勳爠霃� 鞝滉车霅� 鞓堨爼鞛呺媹雼�.
CytomX Therapeutics (CTMX) a annonc茅 qu'il publiera ses r茅sultats financiers du troisi猫me trimestre 2024 le jeudi 7 novembre 2024, apr猫s la fermeture des march茅s am茅ricains. L'entreprise organisera une conf茅rence t茅l茅phonique et un webinaire 脿 17h00 ET / 14h00 PT pour discuter des r茅sultats. Les investisseurs peuvent acc茅der au webinaire via le site web des relations avec les investisseurs de CytomX, et une version archiv茅e sera disponible par la suite.
CytomX Therapeutics (CTMX) hat bekannt gegeben, dass es seine finanziellen Ergebnisse f眉r das dritte Quartal 2024 am Donnerstag, den 7. November 2024, nach Schlie脽ung der US-M盲rkte ver枚ffentlichen wird. Das Unternehmen wird um 17:00 Uhr ET / 14:00 Uhr PT eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen. Investoren k枚nnen 眉ber die Investor-Relations-Website von CytomX auf den Webcast zugreifen, und eine archivierte Version wird anschlie脽end verf眉gbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report third quarter financial results on Thursday, November 7, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at听5:00 p.m. ET听/听2:00 p.m. PT.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX鈥檚 website at听. An archived replay of the webcast will be available on the Company鈥檚 website.
Audio Conference Call:
| 听 | U.S. Dial-in Number:听 | 听 | (800) 715-9871 |
| 听 | 听 | 听 | 听 |
| 听 | International Dial-in Number: | 听 | (646) 307-1963 |
| 听 | 听 | 听 | 听 |
| 听 | Conference ID:听 | 听 | 5171678 |
| 听 | 听 | 听 | 听 |
About听CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY庐听therapeutic platform, CytomX鈥檚 vision is to create safer, more effective therapies for the treatment of cancer. CytomX鈥檚 robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (鈥淎DCs鈥�), T-cell engagers, and immune modulators such as cytokines. CytomX鈥檚 clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule, EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. CX-2051 was discovered in collaboration with Immunogen, now part of AbbVie. CX-801 is an interferon alpha-2b PROBODY庐听cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas,听Bristol听Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit听听and follow us on听听and听.
Company Contact:
Chris Ogden
Chief Financial Officer
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
听
Media Contact:
Redhouse Communications
Teri Dahlman
FAQ
When will CytomX Therapeutics (CTMX) report Q3 2024 earnings?
How can investors access CytomX Therapeutics' (CTMX) Q3 2024 earnings call?
What time is CytomX Therapeutics' (CTMX) Q3 2024 earnings call?
